(Q40694376)

22 September 2017

1 reference

title

Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations (English)

1 reference

22 September 2017

1 reference

1 reference

1 reference

Stewart CF

1

1 reference

PubMed ID

8070032

22 September 2017

language of work or name

1 reference

1 January 1994

1 reference

Cancer Chemotherapy and Pharmacology

22 September 2017

1 reference

22 September 2017

34 Suppl

1 reference

22 September 2017

S76-83

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00684868

22 September 2017

0 references

cites work

Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions

1 reference

12 December 2020

Factors affecting in vitro protein binding of etoposide in humans

1 reference

12 December 2020

Etoposide kinetics in patients with obstructive jaundice

1 reference

12 December 2020

In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy

1 reference

12 December 2020

Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide

1 reference

12 December 2020

Evaluation of aminoglycoside disposition in patients previously treated with cisplatin

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Pharmacodynamics in cancer therapy

1 reference

12 December 2020

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

1 reference

12 December 2020

Pharmacokinetics of high dose etoposide (VP 16-213)

1 reference

12 December 2020

Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer

1 reference

12 December 2020

Etoposide: seeking the best dose and schedule

1 reference

12 December 2020

Changes in the clearance of total and unbound etoposide in patients with liver dysfunction

1 reference

12 December 2020

Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.

1 reference

12 December 2020

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer

1 reference

12 December 2020

Inadequacy of predicted creatinine clearance as guide to chemotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients

1 reference

12 December 2020

Interspecies differences in in vitro etoposide plasma protein binding

1 reference

12 December 2020

Disposition of total and unbound etoposide following high-dose therapy

1 reference

12 December 2020

Phase I pharmacokinetic study of intraperitoneal etoposide

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

12 December 2020

Modeling interpatient pharmacodynamic variability of etoposide.

1 reference

12 December 2020

Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.

1 reference

12 December 2020

Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors

1 reference

12 December 2020

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function

1 reference

12 December 2020

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules

1 reference

12 December 2020

Protein Binding and Kinetics of Drugs in Liver Diseases

1 reference

12 December 2020

Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver.

1 reference

12 December 2020

Clinical pharmacodynamics of continuous-infusion etoposide

1 reference

12 December 2020

Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit.

1 reference

12 December 2020

Human cytochrome P450 metabolism of teniposide and etoposide

1 reference

12 December 2020

Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide

1 reference

12 December 2020

Guide to drug dosage in renal failure

1 reference

12 December 2020

Altered protein binding of etoposide in patients with cancer

1 reference

12 December 2020

Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.

1 reference

12 December 2020

Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.

1 reference

12 December 2020

Relation of systemic exposure to unbound etoposide and hematologic toxicity

1 reference

12 December 2020

Patients at risk of chemotherapy-associated toxicity in small cell lung cancer

1 reference

12 December 2020

Estimation of creatinine clearance in patients with gynecologic cancer

1 reference

12 December 2020

Pharmacokinetics of VP16-213 given by different administration methods

1 reference

12 December 2020

Etoposide pharmacokinetics in patients with normal and abnormal organ function

1 reference

12 December 2020

The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate

1 reference

12 December 2020

Metabolism and excretion of etoposide in isolated, perfused rat liver models

1 reference

12 December 2020

Bioavailability of low-dose oral etoposide

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00684868

1 reference

PubMed ID

8070032

Dimensions Publication ID

22 September 2017

0 references

1 reference

PubMed ID

8070032